Earle A. Chiles Research Institute

  • Neoadjuvant combination therapy for triple-negative breast cancer

    Neoadjuvant combination therapy for triple-negative breast cancer

    A phase II, investigator-initiated clinical trial at Providence Cancer Institute aims to improve survival for patients with triple-negative breast cancer. The trial is available only at Providence.

    Read Article
  • Providence researchers demonstrate antibodies to COVID-19 in breast milk of mothers following vaccination

    Providence researchers demonstrate antibodies to COVID-19 in breast milk of mothers following vaccination

    A new pilot study at Providence Cancer Institute provides promising results of a potential immune benefit for infants from lactating mothers who have received a COVID-19 vaccine.

    Read Article
  • Combination therapy for metastatic thyroid cancer

    Combination therapy for metastatic thyroid cancer

    New clinical trial at Providence Cancer Institute combining targeted therapy with checkpoint immunotherapy for patients with metastatic thyroid cancer.

    Read Article
  • $2M endowed chair funded to help develop new treatments at Providence Cancer Institute

    $2M endowed chair funded to help develop new treatments at Providence Cancer Institute

    Michael Kelley Endowed Chair for Cancer Research awarded to Providence Cancer Institute radiation oncologist, Dr. Marka Crittenden.

    Read Article
  • Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

    Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

    Attendees will have an opportunity to connect with experts in the immunotherapy field at the live virtual event held on Thursday, April 8, 2021.

    Read Article
  • Melanoma studies: can adjuvant immunotherapy improve recurrence-free survival?

    Melanoma studies: can adjuvant immunotherapy improve recurrence-free survival?

    Three new studies at Providence Cancer Institute will investigate the benefits of adjuvant immunotherapy for patients with completely resected melanoma who are at high risk of recurrence.

    Read Article
  • Adoptive cellular therapy for head and neck cancer

    Adoptive cellular therapy for head and neck cancer

    Providence Cancer Institute is the only center in the Pacific Northwest to offer a groundbreaking study of adoptive T-cell therapy ADP-A2M4 in combination with the checkpoint inhibitor pembrolizumab.

    Read Article
  • New studies aim to improve treatments for advanced breast cancer

    New studies aim to improve treatments for advanced breast cancer

    Advancements in treatment and early detection have improved survival for women diagnosed with breast cancer. For patients with locally advanced or metastatic breast cancer, better therapies are needed

    Read Article
  • Providence researchers featured at cancer immunotherapy conference

    Providence researchers featured at cancer immunotherapy conference

    Investigators present latest research in cancer immunotherapy, receive noteworthy awards, at the 35th annual meeting of the Society for Immunotherapy of Cancer.

    Read Article
  • FDA approves Providence Cancer Institute COVID-19 vaccine trial

    FDA approves Providence Cancer Institute COVID-19 vaccine trial

    Providence researchers launch COVID-19 vaccine clinical trial designed for older adults.

    Read Article
  • CAR T-cell therapy for advanced B-cell Non-Hodgkin Lymphoma

    CAR T-cell therapy for advanced B-cell Non-Hodgkin Lymphoma

    Providence Cancer Institute is one of the few highly specialized centers offering adoptive cellular therapy for hematologic malignancies. Chimeric antigen receptor (CAR) T-cell therapy is a revolution

    Read Article
  • Providence cancer research highlighted at ESMO20

    Providence cancer research highlighted at ESMO20

    Providence Cancer Institute joins oncology professionals around the world for ESMO Virtual Congress 2020, the annual meeting of the European Society for Medical Oncology, held online from September 14

    Read Article
  • Melanoma study: are two therapies better than one?

    Melanoma study: are two therapies better than one?

    The incidence of melanoma is increasing faster than other skin cancers. Although surgery can cure early stage melanomas, and many new standard therapies for advanced disease improve survival, few are

    Read Article
  • New grant funding advances head and neck cancer research at Providence Cancer Institute

    Five investigators at Providence Cancer Institute received new funding for immunotherapy research through an internal grant mechanism aimed to improve outcomes for patients with head and neck cancer.

    Read Article
  • Breakthrough radiotherapy for pancreatic cancer

    Breakthrough radiotherapy for pancreatic cancer

    Providence Cancer Institute is the first facility in the Pacific Northwest, and the first community medical center in the country, to offer MRI-guided radiation therapy for patients with pancreatic ca

    Read Article
  • New phase I immuno-oncology study for HPV16+ cancers

    New phase I immuno-oncology study for HPV16+ cancers

    An unmet clinical need exists for patients with cancers associated with human papillomavirus. A new phase I study at Providence Cancer Institute will evaluate a novel biologic therapy in patients with

    Read Article
  • Cancer Immunotherapy Month

    Cancer Immunotherapy Month

    June is Cancer Immunotherapy MonthTM, an initiative to call attention to cancer immunotherapy, a specialized field focused on harnessing the power of the immune system to cure cancer.

    Read Article
  • Providence at forefront of COVID-19 clinical research

    Providence at forefront of COVID-19 clinical research

    Researchers at Providence Cancer Institute swiftly apply expertise in immunology, vaccines and clinical trials to COVID-19 treatment and research.

    Read Article
  • Providence cancer researchers highlighted at ASCO20: Virtual

    Providence cancer researchers highlighted at ASCO20: Virtual

    Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, will join oncology professionals around the world for the 2020 ASCO Virtual Scient

    Read Article
  • New Immunotherapy Approaches for Cutaneous Squamous Cell Carcinoma

    New Immunotherapy Approaches for Cutaneous Squamous Cell Carcinoma

    Is checkpoint immunotherapy better with oncolytic viral therapy in patients with advanced cutaneous squamous cell carcinoma?

    Read Article
  • loading
    Loading More...